RT Journal Article
SR Electronic
T1 Reduced amplification efficiency of the RNA-dependent-RNA-polymerase (RdRp) target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.01.21264408
DO 10.1101/2021.10.01.21264408
A1 Valley-Omar, Ziyaad
A1 Marais, Gert
A1 Iranzadeh, Arash
A1 Naidoo, Michelle
A1 Korsman, Stephen
A1 Maponga, Tongai
A1 Hussey, Hannah
A1 Davies, Mary-Ann
A1 Boulle, Andrew
A1 Doolabh, Deelan
A1 Laubscher, Mariska
A1 Deetlefs, JD
A1 Maritz, Jean
A1 Scott, Lesley
A1 Msomi, Nokukhanya
A1 Tegally, Houriiyah
A1 de Oliveira, Tulio
A1 Bhiman, Jinal
A1 Williamson, Carolyn
A1 Preiser, Wolfgang
A1 Hardie, Diana
A1 Hsiao, Nei-yuan
YR 2021
UL http://medrxiv.org/content/early/2021/10/01/2021.10.01.21264408.abstract
AB Routine SARS-CoV-2 surveillance in the Western Cape region of South Africa (January-August 2021) found a reduced PCR amplification efficiency of the RdRp gene target of the Seegene, Allplex 2019-nCoV diagnostic assay when detecting the Delta variant. We propose that this can be used as a surrogate for variant detection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine (core grant number is 203135/Z/16/Z), Division of Medical Virology in Department of Pathology, University of Cape Town, Observatory 7925, Republic of South Africa, the Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and the Minderoo Foundations, and by a research Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols have been approved by the UCT Faculty of Health Sciences Human Research Ethics Committee (HREC:383/2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study sequences are listed in the supplementary table